Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China ...Middle East

PR Newswire - News
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases...

Hence then, the article about everest medicines announces investigational new drug application acceptance of zetomipzomib in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China )

Apple Storegoogle play

Last updated :

Also on site :